Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of inducement equity awards to newly appointed CFO, Geoffrey Porges. The inducement grants include a stock option for 180,000 shares and performance-based restricted stock units for 90,000 shares. The stock option has an exercise price of $28.55 per share, reflecting the closing price on August 18, 2022. The option vests over four years while performance units depend on achieving specified performance goals. This move aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's strategy to attract top talent.
Schrödinger, Inc. (Nasdaq: SDGR) has appointed Geoffrey Porges as chief financial officer, bringing over 30 years of experience in the biopharmaceutical industry. He will oversee financial operations, investor relations, and corporate affairs as well as strategic planning for the company's pharmaceutical collaborations. Porges, previously at SVB Securities, expressed excitement about contributing to Schrödinger's growth, highlighting a strong balance sheet and revenue outlook. The company's physics-based software platform is revolutionizing drug discovery, enabling faster and cost-efficient therapeutic development.
Schrödinger, Inc. (Nasdaq: SDGR) reported a 38.5 million total revenue for Q2 2022, reflecting a 29% increase from the previous year. Software revenue reached 30.0 million with a 25% rise, while drug discovery revenue surged 48% to 8.5 million. Despite strong revenue growth, the company reported a net loss of 47.7 million, compared to 35.0 million in Q2 2021. Schrödinger is set to begin Phase 1 clinical trials for its MALT1 inhibitor, SGR-1505, in Q4 2022 and maintains a solid cash position of 513 million.
Schrödinger (Nasdaq: SDGR) will disclose its second quarter 2022 financial results on August 4, 2022, after market closure. The company will also host a conference call at 4:30 p.m. ET, accessible via its investor website. Schrödinger, founded in 1990, has developed a physics-based software platform that accelerates the discovery of therapeutics and materials, reducing costs compared to traditional methods. The firm employs over 700 personnel and collaborates with partners globally, aiming to address unmet medical needs.
Schrödinger, Inc. (Nasdaq: SDGR) announced FDA clearance for its investigational new drug (IND) application for SGR-1505, a MALT1 inhibitor. Anticipated to begin a Phase 1 clinical trial in the second half of 2022, the study will target patients with relapsed or refractory B-cell lymphoma. The trial aims to assess the safety and effectiveness of SGR-1505. The company emphasizes the significant medical need for new treatments in this area, promising to explore combination therapies once the recommended dose is established.
Schrödinger, Inc. (Nasdaq: SDGR) is hosting its second annual Educator's Day to discuss the integration of computational tools in education. The event, featuring live webinars from esteemed educators, aims to equip K-12 and university students with modern scientific skills. Keynote speaker Maria Gallardo-Williams highlighted the effectiveness of virtual reality labs developed during the COVID-19 pandemic, which assisted over 50 universities. Schrödinger's software platform accelerates drug and materials discovery, emphasizing hands-on learning and bridging technology gaps in education.
Schrödinger (Nasdaq: SDGR) announced its participation in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 3:30 p.m. ET. The live presentation will be accessible in the investors section of Schrödinger's website and archived for seven days. Schrödinger is renowned for its innovative physics-based software platform that accelerates the discovery of therapeutics and materials, engaging biopharmaceutical and industrial sectors worldwide.
Schrödinger, Inc. (Nasdaq: SDGR) has appointed Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi, a former executive vice president at Red Hat, will also serve on the Audit Committee. His extensive experience in enterprise software is expected to support Schrödinger's growth and mission to enhance human health. Schrödinger specializes in a physics-based software platform that accelerates the discovery of therapeutics and materials, aiming to improve efficiency and reduce costs significantly compared to traditional methods.
Schrödinger (Nasdaq: SDGR) announced its participation in the Citi Biotech Virtual Co-Panel Day on May 18, 2022, at 10:00 a.m. ET. Karen Akinsanya, president of R&D, Therapeutics, will discuss Software, AI, and Bioinformatics in Drug Development. The panel will be accessible live via the investors section of Schrödinger’s website and will be archived for a week afterward. Schrödinger's innovative software platform significantly enhances the discovery of therapeutics and materials, supporting clients globally since its inception in 1990.
Schrödinger, Inc. (SDGR) reported a strong first quarter of 2022 with total revenue of $48.7 million, representing a 51% increase year-over-year. Software revenue reached $33.1 million, a 26% rise, driven by customer adoption. Gross profit was $28 million, a 73% increase, while the company recorded a net loss of $34.5 million. Schrödinger is on track with its pipeline, notably planning an IND submission for its MALT1 inhibitor, SGR-1505, in the first half of 2022. The company maintains its 2022 financial outlook, predicting total revenue of $161 million to $181 million.